BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9402328)

  • 1. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.
    Desikan KR; Dhodapkar MV; Hough A; Waldron T; Jagannath S; Siegel D; Barlogie B; Tricot G
    Leuk Lymphoma; 1997 Oct; 27(3-4):315-9. PubMed ID: 9402328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
    Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
    Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.
    Siragusa S; Morice W; Gertz MA; Kyle RA; Greipp PR; Lust JA; Witzig TE; Lacy MQ; Zeldenrust SR; Rajkumar SV; Russell SJ; Hayman SR; Buadi F; Kumar SK; Dingli D; Dispenzieri A
    Ann Hematol; 2011 Jan; 90(1):101-6. PubMed ID: 20645101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
    Kourelis TV; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Zeldenrust S; Leung N; Kyle RA; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Rajkumar SV; McCurdy A; Dispenzieri A
    J Clin Oncol; 2013 Dec; 31(34):4319-24. PubMed ID: 24145344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The occurrence of Al amyloidosis (light-chain amyloidosis) in patients with multiple myeloma in Lower Silesia Region, Poland.
    Usnarska-Zubkiewicz L; Hołojda J; Jeleń M; Zubkiewicz-Zarębska A; Dębski J; Kuliczkowski K
    Adv Clin Exp Med; 2014; 23(2):235-44. PubMed ID: 24913114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic factors in light chain amyloidosis].
    Jávorniczky NR; Bodó I; Masszi T; Mikala G
    Orv Hetil; 2015 Sep; 156(39):1577-84. PubMed ID: 26550915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.
    Madan S; Dispenzieri A; Lacy MQ; Buadi F; Hayman SR; Zeldenrust SR; Rajkumar SV; Gertz MA; Kumar SK
    Mayo Clin Proc; 2010 Mar; 85(3):232-8. PubMed ID: 20194151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience.
    Hernández-Reyes J; Galo-Hooker E; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Rev Invest Clin; 2012; 64(6 Pt 2):604-8. PubMed ID: 23593777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].
    Liu Y; You HY; Yan LZ; Jin S; Shang JJ; Shi XL; Yan S; Yao WQ; Wu DP; Liu W; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):330-335. PubMed ID: 35680633
    [No Abstract]   [Full Text] [Related]  

  • 10. Free light chains ratio as a marker to estimate prognosis and survival in patients with multiple myeloma and primary amyloidosis.
    Radovic V; Mijuskovic Z; Tukic Lj; Djurdjevic P; Stojanovic J; Zlatkovic M
    J BUON; 2012; 17(1):110-5. PubMed ID: 22517703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystalline light-chain deposition and amyloidosis in the thyroid gland and kidneys of a patient with myeloma.
    Hirota S; Miyamoto M; Kasugai T; Kitamura Y; Morimura Y
    Arch Pathol Lab Med; 1990 Apr; 114(4):429-31. PubMed ID: 2108650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.
    Decourt A; Gondouin B; Delaroziere JC; Brunet P; Sallée M; Burtey S; Dussol B; Ivanov V; Costello R; Couchoud C; Jourde-Chiche N
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):431-41. PubMed ID: 26728585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracorporeal membrane oxygenation as bridge-to-decision in acute heart failure due to systemic light-chain amyloidosis.
    Mancio Silva J; Fontes-Carvalho R; Valente D; Almeida C; Cruz AJ; Tente D; Coelho H; Oliveira M; Albuquerque A; Ribeiro VG
    Am J Case Rep; 2015 Mar; 16():174-81. PubMed ID: 25803181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin light chain amyloidosis and the kidney.
    Gertz MA; Lacy MQ; Dispenzieri A
    Kidney Int; 2002 Jan; 61(1):1-9. PubMed ID: 11786079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.
    Nasr SH; Said SM; Valeri AM; Sethi S; Fidler ME; Cornell LD; Gertz MA; Dispenzieri A; Buadi FK; Vrana JA; Theis JD; Dogan A; Leung N
    Kidney Int; 2013 Mar; 83(3):463-70. PubMed ID: 23302715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.
    Jiang N; Qi C; Trieu Y; Reece D; Chang H
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1790-5. PubMed ID: 21658460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.